Dairy products and kidney function decline after myocardial infarction: A prospective analysis in the Alpha Omega Cohort

Anniek C. van Westing; Esther Cruijsen; Trudy Voortman; Johanna M. Geleijnse

doi:10.1016/j.clnu.2023.05.024

Dairy products and kidney function decline after myocardial infarction: A prospective analysis in the Alpha Omega Cohort

Anniek C. van Westing^*, Esther Cruijsen, Trudy Voortman, Johanna M. Geleijnse

^*Corresponding author for this work

Epidemiology

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

32 Downloads (Pure)

Abstract

Background & aims: Population-based studies have shown both beneficial and neutral associations between dairy consumption and kidney function outcomes. We investigated the association between dairy products and kidney function decline in drug-treated post-myocardial infarction (MI) patients. Methods: We analysed data of 2169 post–MI patients (aged 60–80 years, 81% male) of the Alpha Omega Cohort. Dietary data were collected at baseline (2002–2006) using a validated 203-item food frequency questionnaire. The 2021 Chronic Kidney Disease Epidemiology (CKD-EPI) equation was used to estimate 40-months change in creatinine-cystatin C based glomerular filtration rate (eGFR_cr-cysC, mL/min per 1.73 m²). Beta coefficients and 95% confidence intervals (CIs) for dairy products in relation to annual eGFR_cr-cysC change were obtained from multivariable linear regression, adjusted for age, sex, energy intake, and other lifestyle and dietary factors. Results: Baseline energy-adjusted median intakes were 64 g/day for total milk, 20 g/day for hard cheeses, 18 g/day for plain yogurt, and 70 g/day for dairy desserts. Mean ± SD eGFR_cr-cysC was 84 ± 20 (13% with CKD), and annual eGFR_cr-cysC change was −1.71 ± 3.85. In multivariable models, high vs. low intakes of total milk, cheese, and dairy desserts were not associated with annual eGFR_cr-cysC change (β_{total milk}: −0.21 [−0.60; 0.19], β_cheese: −0.08 [−0.52; 0.36], β_{dairy desserts}: −0.24 [−0.72; 0.24]). High vs. low intake of yogurt was adversely associated with annual eGFR_cr-cysC change (β_{total yogurt}: −0.50 [−0.91;-0.09]), but subsequent spline analyses showed no clear dose–response association. Conclusions: Intakes of milk, cheese or dairy desserts were not associated with a delayed kidney function decline after MI. The observed adverse association for yogurt should be interpreted with caution. Our findings require confirmation in other cohorts of coronary heart disease patients.

Original language	English
Pages (from-to)	1501-1509
Number of pages	9
Journal	Clinical Nutrition
Volume	42
Issue number	8
Early online date	3 Jun 2023
DOIs	https://doi.org/10.1016/j.clnu.2023.05.024
Publication status	Published - Aug 2023

Bibliographical note

Funding Information:
A.C. van Westing was supported by a grant from Jaap Schouten Foundation (grant no. JSF_SU_10_2018 ). T. Voortman reports grants from Erasmus MC , Erasmus University , Delft University , The European Society for Clinical Nutrition and Metabolism, National Dairy Association , and European Union. J.M. Geleijnse reports grants from the Ministry of Health, Welfare and Sports in the Netherlands, and the European Union. E. Cruijsen declares no conflict of interest. Data collection for the Alpha Omega Cohort was funded by the Dutch Heart Foundation (grant no. 200T401 ) and the National Institutes of Health (USA, NIH/NHLBI grant no. R01HL076200 ). Funding agencies had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript.

Publisher Copyright: © 2023 The Author(s)

Access to Document

10.1016/j.clnu.2023.05.024Licence: CC BY

1-s2.0-S0261561423001668-mainFinal published version, 707 KBLicence: CC BY

Cite this

@article{eb74d0e8781646d8911e8284173142c2,

title = "Dairy products and kidney function decline after myocardial infarction: A prospective analysis in the Alpha Omega Cohort",

abstract = "Background & aims: Population-based studies have shown both beneficial and neutral associations between dairy consumption and kidney function outcomes. We investigated the association between dairy products and kidney function decline in drug-treated post-myocardial infarction (MI) patients. Methods: We analysed data of 2169 post–MI patients (aged 60–80 years, 81% male) of the Alpha Omega Cohort. Dietary data were collected at baseline (2002–2006) using a validated 203-item food frequency questionnaire. The 2021 Chronic Kidney Disease Epidemiology (CKD-EPI) equation was used to estimate 40-months change in creatinine-cystatin C based glomerular filtration rate (eGFRcr-cysC, mL/min per 1.73 m2). Beta coefficients and 95% confidence intervals (CIs) for dairy products in relation to annual eGFRcr-cysC change were obtained from multivariable linear regression, adjusted for age, sex, energy intake, and other lifestyle and dietary factors. Results: Baseline energy-adjusted median intakes were 64 g/day for total milk, 20 g/day for hard cheeses, 18 g/day for plain yogurt, and 70 g/day for dairy desserts. Mean ± SD eGFRcr-cysC was 84 ± 20 (13% with CKD), and annual eGFRcr-cysC change was −1.71 ± 3.85. In multivariable models, high vs. low intakes of total milk, cheese, and dairy desserts were not associated with annual eGFRcr-cysC change (βtotal milk: −0.21 [−0.60; 0.19], βcheese: −0.08 [−0.52; 0.36], βdairy desserts: −0.24 [−0.72; 0.24]). High vs. low intake of yogurt was adversely associated with annual eGFRcr-cysC change (βtotal yogurt: −0.50 [−0.91;-0.09]), but subsequent spline analyses showed no clear dose–response association. Conclusions: Intakes of milk, cheese or dairy desserts were not associated with a delayed kidney function decline after MI. The observed adverse association for yogurt should be interpreted with caution. Our findings require confirmation in other cohorts of coronary heart disease patients.",

author = "{van Westing}, {Anniek C.} and Esther Cruijsen and Trudy Voortman and Geleijnse, {Johanna M.}",

note = "Funding Information: A.C. van Westing was supported by a grant from Jaap Schouten Foundation (grant no. JSF_SU_10_2018 ). T. Voortman reports grants from Erasmus MC , Erasmus University , Delft University , The European Society for Clinical Nutrition and Metabolism, National Dairy Association , and European Union. J.M. Geleijnse reports grants from the Ministry of Health, Welfare and Sports in the Netherlands, and the European Union. E. Cruijsen declares no conflict of interest. Data collection for the Alpha Omega Cohort was funded by the Dutch Heart Foundation (grant no. 200T401 ) and the National Institutes of Health (USA, NIH/NHLBI grant no. R01HL076200 ). Funding agencies had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2023",

month = aug,

doi = "10.1016/j.clnu.2023.05.024",

language = "English",

volume = "42",

pages = "1501--1509",

journal = "Clinical Nutrition",

issn = "0261-5614",

publisher = "Churchill Livingstone",

number = "8",

}

TY - JOUR

T1 - Dairy products and kidney function decline after myocardial infarction

T2 - A prospective analysis in the Alpha Omega Cohort

AU - van Westing, Anniek C.

AU - Cruijsen, Esther

AU - Voortman, Trudy

AU - Geleijnse, Johanna M.

N1 - Funding Information: A.C. van Westing was supported by a grant from Jaap Schouten Foundation (grant no. JSF_SU_10_2018 ). T. Voortman reports grants from Erasmus MC , Erasmus University , Delft University , The European Society for Clinical Nutrition and Metabolism, National Dairy Association , and European Union. J.M. Geleijnse reports grants from the Ministry of Health, Welfare and Sports in the Netherlands, and the European Union. E. Cruijsen declares no conflict of interest. Data collection for the Alpha Omega Cohort was funded by the Dutch Heart Foundation (grant no. 200T401 ) and the National Institutes of Health (USA, NIH/NHLBI grant no. R01HL076200 ). Funding agencies had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: © 2023 The Author(s)

PY - 2023/8

Y1 - 2023/8

N2 - Background & aims: Population-based studies have shown both beneficial and neutral associations between dairy consumption and kidney function outcomes. We investigated the association between dairy products and kidney function decline in drug-treated post-myocardial infarction (MI) patients. Methods: We analysed data of 2169 post–MI patients (aged 60–80 years, 81% male) of the Alpha Omega Cohort. Dietary data were collected at baseline (2002–2006) using a validated 203-item food frequency questionnaire. The 2021 Chronic Kidney Disease Epidemiology (CKD-EPI) equation was used to estimate 40-months change in creatinine-cystatin C based glomerular filtration rate (eGFRcr-cysC, mL/min per 1.73 m2). Beta coefficients and 95% confidence intervals (CIs) for dairy products in relation to annual eGFRcr-cysC change were obtained from multivariable linear regression, adjusted for age, sex, energy intake, and other lifestyle and dietary factors. Results: Baseline energy-adjusted median intakes were 64 g/day for total milk, 20 g/day for hard cheeses, 18 g/day for plain yogurt, and 70 g/day for dairy desserts. Mean ± SD eGFRcr-cysC was 84 ± 20 (13% with CKD), and annual eGFRcr-cysC change was −1.71 ± 3.85. In multivariable models, high vs. low intakes of total milk, cheese, and dairy desserts were not associated with annual eGFRcr-cysC change (βtotal milk: −0.21 [−0.60; 0.19], βcheese: −0.08 [−0.52; 0.36], βdairy desserts: −0.24 [−0.72; 0.24]). High vs. low intake of yogurt was adversely associated with annual eGFRcr-cysC change (βtotal yogurt: −0.50 [−0.91;-0.09]), but subsequent spline analyses showed no clear dose–response association. Conclusions: Intakes of milk, cheese or dairy desserts were not associated with a delayed kidney function decline after MI. The observed adverse association for yogurt should be interpreted with caution. Our findings require confirmation in other cohorts of coronary heart disease patients.

AB - Background & aims: Population-based studies have shown both beneficial and neutral associations between dairy consumption and kidney function outcomes. We investigated the association between dairy products and kidney function decline in drug-treated post-myocardial infarction (MI) patients. Methods: We analysed data of 2169 post–MI patients (aged 60–80 years, 81% male) of the Alpha Omega Cohort. Dietary data were collected at baseline (2002–2006) using a validated 203-item food frequency questionnaire. The 2021 Chronic Kidney Disease Epidemiology (CKD-EPI) equation was used to estimate 40-months change in creatinine-cystatin C based glomerular filtration rate (eGFRcr-cysC, mL/min per 1.73 m2). Beta coefficients and 95% confidence intervals (CIs) for dairy products in relation to annual eGFRcr-cysC change were obtained from multivariable linear regression, adjusted for age, sex, energy intake, and other lifestyle and dietary factors. Results: Baseline energy-adjusted median intakes were 64 g/day for total milk, 20 g/day for hard cheeses, 18 g/day for plain yogurt, and 70 g/day for dairy desserts. Mean ± SD eGFRcr-cysC was 84 ± 20 (13% with CKD), and annual eGFRcr-cysC change was −1.71 ± 3.85. In multivariable models, high vs. low intakes of total milk, cheese, and dairy desserts were not associated with annual eGFRcr-cysC change (βtotal milk: −0.21 [−0.60; 0.19], βcheese: −0.08 [−0.52; 0.36], βdairy desserts: −0.24 [−0.72; 0.24]). High vs. low intake of yogurt was adversely associated with annual eGFRcr-cysC change (βtotal yogurt: −0.50 [−0.91;-0.09]), but subsequent spline analyses showed no clear dose–response association. Conclusions: Intakes of milk, cheese or dairy desserts were not associated with a delayed kidney function decline after MI. The observed adverse association for yogurt should be interpreted with caution. Our findings require confirmation in other cohorts of coronary heart disease patients.

UR - http://www.scopus.com/inward/record.url?scp=85161567814&partnerID=8YFLogxK

U2 - 10.1016/j.clnu.2023.05.024

DO - 10.1016/j.clnu.2023.05.024

M3 - Article

C2 - 37308369

AN - SCOPUS:85161567814

SN - 0261-5614

VL - 42

SP - 1501

EP - 1509

JO - Clinical Nutrition

JF - Clinical Nutrition

IS - 8

ER -

Dairy products and kidney function decline after myocardial infarction: A prospective analysis in the Alpha Omega Cohort

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this